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PHARMACOECONOMIC EVALUATION OF
VASOTEC® IN HYPERTENSIVE PATIENTS WITH
CONGESTIVE HEART FAILURE: AN UPDATE OF
THE RETROSPECTIVE CANADIAN ANALYSIS
BASED ON THE STUDIES OF LEFT
VENTRICULAR DYSFUNCTION (SOLVD)
Desjardins B1, Marceau C1, Cook JR2, Glick HA3
1Merck Frosst Canada Ltd, Kirkland, QC, Canada; 2Merck and
Co, Blue Bell, PA, USA; 3University of Pennsylvania,
Philadelphia, PA, USA
OBJECTIVES: ACE inhibitors are a potent therapy for
congestive heart failure associated with left ventricular
dysfunction and hypertension. Taking a hospital perspec-
tive, we report an update of a previous analysis of the
health economic consequences of treating these hyper-
tensive patients with enalapril in the Canadian setting.
METHODS: A decision analytic model was used to
project survival probabilities and hospitalization rates
beyond the trial observation period (5 years) using a sec-
ondary analysis of a subset of 1917 hypertensive patients
with or without overt symptoms of congestive heart
failure from the Studies of Left Ventricular Dysfunction
(SoLVD). Patients who had HBP, deﬁned by either an 
elevated systolic (140mmHg) or diastolic (90mmHg)
blood pressure were selected for this study. We updated
the model with Canadian cost inputs for fatal and non-
fatal hospitalization, ambulatory care, death outside of
the hospital, and enalapril for year 2003. Costs and 
beneﬁts were discounted at a 5% annual rate. RESULTS:
Over a projected 5-year period, patients treated primar-
ily with enalapril twice-daily gained 0.18 life-years and
experienced 0.4 fewer hospitalizations per patient com-
pared to those receiving placebo. Over their lifetimes,
patients treated with enalapril were projected to gain 2.14
life-years and experience 0.36 fewer hospitalizations. The
incremental cost-utility ratios for enalapril versus placebo
shown net cost savings of CAN$2309 over 5 years and
CAN$3552 per QALY gained over patients’ lifetimes. For
the subset of patients with overt symptoms of congestive
heart failure, enalapril was cost saving in both the 5-year
and lifetime projections. These results were not sensi-
tive to changes in model parameters. CONCLUSION:
Enalapril treatment for hypertensive patients with left
ventricular dysfunction is projected to extend life ex-
pectancy, reduce hospitalizations, and to be either cost
saving or highly cost-effective in Canada.
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LONG-TERM COST-EFFECTIVENESS OF
PRIMARY ANGIOPLASTY COMPARED TO
FIBRINOLYSIS IN ACUTE MYOCARDIAL
INFARCTION
Sridhar K, Mahon JL
University of Western Ontario, London, ON, Canada
Primary angioplasty (PA) is clinically superior in reduc-
ing the risk of mortality and stroke at 30 days compared
with ﬁbrinolysis. OBJECTIVES: To assess the long-term
incremental cost effectiveness of PA compared with ﬁbri-
nolysis and the overall certainty of the baseline analy-
sis using probabilistic sensitivity analysis. METHODS:
Long-term costs and effects of PA and ﬁbrinolysis were
compared using Markov modeling. Four possible transi-
tion states were included in each arm: remaining asymp-
tomatic, myocardial infarction, revascularization and
dead. Patients could transition between the ﬁrst three
states with cycle intervals set at one year. The “dead”
state was the absorbing state with no further transition.
Transition probabilities remained ﬁxed between states
throughout the cycles. The termination condition was 
set a ten cycles or years. Costs for the transition states
included direct costs and estimates of productivity losses.
Outcomes were derived from available clinical literature.
Discount rates were 5% for costs and 3% for beneﬁts
over time. The incremental cost effectiveness ratio was
obtained at the end of 10 cycles. Parameter distributions
were created to reﬂect the overall uncertainty of the point
estimates for clinical outcomes and costs, which were
included in the probabilistic analysis. Monte Carlo simu-
lation using 1,000 sample trials was performed for the
probabilistic analysis. RESULTS: After 10 years, the
model predicted the total mortality with PA would be
20.9% (2.1% annualized) compared with 30.3% (3%
annualized) in the ﬁbrinolysis arm. Cumulative reinfarc-
tions would be 11.5% in the primary angioplasty arm
and 20.3% in the ﬁbrinolysis arm. Cumulative rates for
revascularization would be 65% in the primary angio-
plasty arm and 51.9% in the thrombolysis arm. Proba-
bilistic sensitivity analysis suggested that in nearly 80%
of sample clinical trials, PA was economically dominant
over ﬁbrinolysis. CONCLUSIONS: The model predicts
that PA would be dominant and will have a lower rate of
long-term mortality and myocardial infarction, but with
more revascularization procedures compared with 
ﬁbrinolysis.
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SWITCHING PATIENTS TO ROSUVASTATIN
FROM ATORVASTATIN OR OTHER STATINS IS
COST-EFFECTIVE: PHARMACOECONOMIC
ANALYSIS OF MERCURY I
James M1, Brown J2, Schuster H3
1AstraZeneca UK Ltd, Macclesﬁeld, Cheshire, United
Kingdom; 2AstraZeneca, Macclesﬁeld, Cheshire, United
Kingdom; 3INFOGEN Medizinische Genetik GmbH, Berlin,
Germany
OBJECTIVE: To assess the cost-effectiveness of switch-
ing patients from atorvastatin (ATV), simvastatin (SIM)
or pravastatin (PRA) to rosuvastatin (Crestor®; RSV),
from the perspective of a UK primary health care
provider. METHODS: The clinical beneﬁt assessed was
the proportion of patients treated to the European Ath-
erosclerosis Society low-density lipoprotein cholesterol
(LDL-C) goal (<3mmol/L). Clinical data were taken from
Measuring Effective Reductions in Cholesterol Using
661Abstracts
Rosuvastatin therapY I (MERCURY I) trial in which
3140 adults with, or at risk of, coronary heart disease ini-
tially received a ﬁxed daily dose of RSV 10mg, ATV 
10 or 20mg, PRA 40mg or SIM 20mg. After 8 weeks’
treatment, patients were randomised to remain on treat-
ment or to switch treatments as follows: from ATV 
10mg, SIM 20mg, PRA 40mg to RSV 10mg or from
ATV 20mg to RSV 10 or 20mg for a further 8 weeks. In
a decision-analysis model, it was assumed that patients
not achieving goal on an alternative statin after 8 weeks
would be switched to RSV. Costs for drug acquisition,
primary care physician visits, nurse visits and laboratory
tests were included where appropriate. Cost-effectiveness
was expressed as the cost per patient treated to LDL-C
goal over a 16-week period. RESULTS: Initiating and
maintaining patients on RSV was more cost-effective than
either 1) initiating and maintaining on another statin; 
or 2) switching from another statin to RSV 10mg. Com-
pared with continuing on ATV, PRA or SIM, switching
to RSV would treat more patients to goal at an incre-
mental cost of €17–117 per extra patient treated to goal.
CONCLUSIONS: Initiating and maintaining patients on
RSV were more cost-effective than switching from the
other statins to RSV. For patients intially receiving other
statins, switching to RSV treated more patients to goal at
relatively little additional total cost while drug costs were
equivalent or lower.
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A COST-EFFECTIVENESS ANALYSIS OF TAXUSTM
DRUG-ELUTING STENT IN THE UK
Wenk-Lang A1, Knight C2
1Boston Scientiﬁc International, La Garenne Colombes,
France, France; 2Heron Evidence Development Ltd,
Letchworth, United Kingdom
Coronary stents (metal mesh tube) are routinely used with
coronary angioplasty for the treatment of ischaemic heart
disease. As many as 25% of patients need reinterventions
post conventional coronary stenting due to re-narrowing
of the treated artery. OBJECTIVE: The objective is to
assess the total 6-month cost and the incremental cost-
utility of the TAXUSTM stent (TAXUS), a paclitaxel-
eluting coronary stent system, compared to conventional
stents (CS). METHOD: A decision analytical model was
developed to assess the 6-month cost and the incremen-
tal cost-utility of TAXUS compared to CS. The study
takes a UK NHS perspective. Clinical event rates for the
TAXUS and CS were taken from TAXUS II clinical trial.
Utility values were sourced from the literature. Unit cost
data were based on UK published sources. RESULTS:
Expected costs at 6 months were £4154 for CS and £4386
for TAXUS in the treated population. Compared to CS
TAXUS was cost saving in diabetic patients (CS £4546
vs. TAXUS £4152), cost neutral in small vessels (CS
£4301 vs TAXUS £4342) and slightly cost additive in
long lesions (CS £4306 vs TAXUS £4425). Most of the
initial increase in procedure cost is offset due to savings
in fewer repeat procedures. The incremental cost-utility
of TAXUS compared to CS ranged from £32,381/ QALY
in the total population to £4,500/ QALY in patients with
small vessels and to £13,500/ QALY in patients with long
lesions. In diabetic patients TAXUS was the dominant
strategy. CONCLUSIONS: Most of the initial increase in
procedural costs with TAXUS is offset due to savings in
repeat procedures. In some high-risk patient groups such
as diabetics and those with small vessels TAXUS is cost
saving or cost neutral. In all patient groups, TAXUS is a
cost-effective new treatment modality for patients with
coronary artery disease.
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LONG-TERM COST-EFFECTIVENESS OF
INVASIVE STRATEGY IN PATIENT WITH
UNSTABLE CORONARY ARTERY DISEASE—
RESULTS FROM THE FRISC-II TRIAL
Levin LÅ1, Janzon M2, Swahn E2
1Center for Medical Technology Assessment CMT, Linköping,
Sweden; 2Linköping Universitet, Linköping, Sweden
OBJECTIVES: The use of early coronary catheterization
and revascularization in unstable coronary artery disease
(UCAD) varies, which could have important conse-
quences for patients as well as long-term costs. The 
objective of this study was to estimate the long-term 
cost-effectiveness and cost-utility ratios of this strategy.
METHODS: We analysed data in the open randomized,
clinical FRISC II invasive trial, which consisted of total
2457 patients, with signs and symptoms of UCAD. We
prospectively recorded the patients’ use of health services
as well as productivity losses. Health states scores were
obtained within the trial ﬁve times during the 2-years
follow-up. Results were analysed in both a societal and 
a health care provider perspective. The uncertainty was
handled using the net-beneﬁt approach. RESULTS: There
was a signiﬁcant 1.74% absolute reduction in mortality
in the invasive compared to the non-invasive group at
two-years follow-up. The difference in mean total cost
was SEK 11,386 $1,467). This difference was not signif-
icant. The estimated cost per quality adjusted life year
(QALY) gained for the invasive strategy, based on within
trial results and projected life expectancy, was SEK
22,873 ($2,948). The estimated cost per life year gained
was SEK 57,651 ($7,429). If costs of added life years were
included the cost per quality adjusted life year was SEK
78,077 ($10,061). CONCLUSIONS: Invasive strategy in
patients with unstable angina or non-ST-segment eleva-
tion myocardial infarction, was in the long-term per-
spective shown to be cost-effective. The results were
consistent in all subgroups.
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COST-EFFECTIVENESS ANALYSIS OF
CITICOLINE VS CONVENTIONAL TREATMENT
IN STROKE PATIENTS
Casado AJ1, Lozano R2, Ibarz R1, Herdman M1
13D Health Research, Barcelona, Spain; 2Grupo Ferrer S.A,
Barcelona, Spain
